SCPH.OQ
Latest Trade
4.38USDChange
--(--)Today's Range
-
--52 Week Range
-
7.65As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 4.38 |
|---|---|
Open | -- |
Volume | -- |
3M AVG Volume | 0.99 |
Today's High | -- |
Today's Low | -- |
52 Week High | 7.65 |
52 Week Low | 2.46 |
Shares Out (MIL) | 18.63 |
Market Cap (MIL) | 84.97 |
Forward P/E | -2.67 |
Dividend (Yield %) | -- |
Scpharmaceuticals Qtrly Loss Per Share $0.31
Scpharmaceuticals Provides Furoscix Update And Announces Completion Of $20 Mln Term Loan Agreement
scPharmaceuticals Inc. Reports Q2 Loss Per Share $0.53
scPharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in developing pharmaceutical products for subcutaneous delivery. The Company offers sc2Wear Infusor, which is a small pump that attaches to the body using a standard medical adhesive. The sc2Wear Infusor injects the drug into the body slowly, similar to an intravenous (IV) drip. The Company's products administered subcutaneously through the sc2Wear Infusor. The Company’s pipeline programs include: scFurosemide lead product candidate, Furoscix, consists of its proprietary subcutaneous formulation of furosemide delivered via sc2Wear Infusor for diuresis in heart failure patients outside of the acute care setting. The Company has completed two pivotal clinical studies, four exploratory clinical studies, and 12 human factor studies for Furoscix, and scCeftriaxone an antibiotic used intravenously for the treatment of infections caused by gram-positive and gram-negative organisms.
Industry
Biotechnology & Drugs
Executive Leadership
Jack A. Khattar
Chairman of the Board,Director
John H. Tucker
President, Chief Executive Officer, Principal Financial Officer, Director
Rachael Nokes
Principal Accounting Officer
Minnie Baylor-Henry
Director
Mason Freeman
Director
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | -- |
Price To Book (MRQ) | 1.47 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 32.55 |
LT Debt To Equity (MRQ) | 32.55 |
Return on Investment (TTM) | -32.10 |
Return on Equity (TTM) | -29.42 |
* SCPHARMACEUTICALS INC. REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
* QTRLY NET LOSS PER SHARE $0.80 Source text for Eikon: Further company coverage:
* RA CAPITAL MANAGEMENT, LLC REPORTS 16.2 PERCENT PASSIVE STAKE IN SCPHARMACEUTICALS INC AS OF NOVEMBER 17 - SEC FILING Source text for Eikon: (http://bit.ly/2Bzh23r) Further company coverage:
* SUN PHARMACEUTICAL INDUSTRIES LIMITED REPORTS 12.3 PERCENT STAKE IN SCPHARMACEUTICALS INC AS OF NOVEMBER 21 - SEC FILING
* ScPharmaceuticals Inc shares open at $14.25 in debut on the NASDAQ versus IPO price of $14.00 per share Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.